These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Actual therapeutic options in the treatment of generalized anxiety disorders]. Delini-Stula A, Bondolfi G, Holsboer-Trachsler E. Rev Med Suisse; 2010 Jun 30; 6(255):1370-4. PubMed ID: 20684132 [Abstract] [Full Text] [Related]
43. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Baldwin DS, Polkinghorn C. Int J Neuropsychopharmacol; 2005 Jun 30; 8(2):293-302. PubMed ID: 15576000 [Abstract] [Full Text] [Related]
44. [Therapy with antidepressive and tranquilizing agents]. Barocka A. Fortschr Med; 1984 Aug 30; 102(31-32):775-9. PubMed ID: 6148296 [Abstract] [Full Text] [Related]
45. [New proposals for the development of the concepts of neurotic anxiety, major depression and panic attack]. Xhenseval B. Acta Psychiatr Belg; 1985 Aug 30; 85(4):480-508. PubMed ID: 2865869 [Abstract] [Full Text] [Related]
46. Pharmacologic treatment of anxiety disorders. Mavissakalian M. J Clin Psychiatry; 1982 Dec 30; 43(12):487-91. PubMed ID: 6131065 [Abstract] [Full Text] [Related]
47. Generalized anxiety disorder. Hoehn-Saric R, McLeod DR. Psychiatr Clin North Am; 1985 Mar 30; 8(1):73-88. PubMed ID: 2859581 [Abstract] [Full Text] [Related]
48. Understanding and treating depression in anxious patients. Dubovsky SL. J Clin Psychiatry; 1990 Oct 30; 51 Suppl():3-8; discussion 14-7. PubMed ID: 1976623 [Abstract] [Full Text] [Related]
49. Diagnosis and management of generalized anxiety disorder. Roerig JL. J Am Pharm Assoc (Wash); 1999 Oct 30; 39(6):811-21; quiz 877-9. PubMed ID: 10609447 [Abstract] [Full Text] [Related]
50. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. Cohn JB, Wilcox CS. J Clin Psychiatry; 1986 Aug 30; 47(8):409-12. PubMed ID: 2874128 [Abstract] [Full Text] [Related]
51. The safety of SSRIs in generalised anxiety disorder: any reason to be anxious? Masand PS, Gupta S. Expert Opin Drug Saf; 2003 Sep 30; 2(5):485-93. PubMed ID: 12946249 [Abstract] [Full Text] [Related]
52. [Trazodone Contramid® in clinical practice: personalizing antidepressant intervention]. Fagiolini A, Amodeo G, Goracci A, Blardi P. Riv Psichiatr; 2016 Sep 30; 51(4):123-128. PubMed ID: 27727261 [Abstract] [Full Text] [Related]
53. The diagnostic validity of anxiety disorders and their relationship to depressive illness. Breier A, Charney DS, Heninger GR. Am J Psychiatry; 1985 Jul 30; 142(7):787-97. PubMed ID: 2861752 [Abstract] [Full Text] [Related]
54. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U. J Clin Psychiatry; 1995 Jul 30; 56 Suppl 6():37-42. PubMed ID: 7649972 [Abstract] [Full Text] [Related]
55. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Uhlenhuth EH, Balter MB, Ban TA, Yang K. Depress Anxiety; 1999 Jul 30; 9(3):107-16. PubMed ID: 10356648 [Abstract] [Full Text] [Related]
56. [Drug treatment of anxiety disorders]. Corfdir C, Pelissolo A. Rev Prat; 2019 Nov 30; 69(9):981-984. PubMed ID: 32237616 [Abstract] [Full Text] [Related]
57. Psychopharmacologic treatment of children and adolescents with anxiety disorders. Strawn JR, Sakolsky DJ, Rynn MA. Child Adolesc Psychiatr Clin N Am; 2012 Jul 30; 21(3):527-39. PubMed ID: 22800992 [Abstract] [Full Text] [Related]